ERBB2 and breast cancer: To address this question, we assessed IMD incidence and survival among patients with HER2-positive breast cancer who were treated with dual anti-HER2 therapy versus trastuzumab monotherapy; we also performed meta-analysis of IMD incidence in patients receiving trastuzumab versus chemotherapy, observation, or another HER2-targeted agent.